Introduction to NDC Codes
The National Drug Code (NDC) is a unique, three-segment number used by the FDA to identify drug products. It consists of a labeler code, a product code, and a package code. Understanding the NDC is crucial for tracking and managing pharmaceutical products, including their pricing and market trends[5].
Drug Identification: IMATINIB MESYLATE 100 MG TAB
The NDC code 00378-2245 corresponds to IMATINIB MESYLATE 100 MG TAB, a medication used primarily in the treatment of certain types of cancer, such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
Current Pricing Trends
As of the latest data available, the price per unit for IMATINIB MESYLATE 100 MG TAB (NDC 00378-2245) has shown some fluctuations:
- December 2024: $0.66780 per unit
- November 2024: $0.64236 per unit
- October 2024: $0.54917 per unit
- September 2024: $0.50016 per unit[2].
These prices indicate a general trend of slight increases over the recent months.
Market Context: Pharmaceutical Pricing
Pharmaceutical pricing in the U.S. is significantly higher compared to other regions. For instance, the average price per unit in the U.S. was 5.5 times as high as in the OECD (excluding the U.S.) and 7.7 times as high as in the rest of the world (excluding the U.S.) in 2022[4].
Biopharma and Biotech Market Growth
The biopharma and biotech industries, which include drugs like IMATINIB MESYLATE, are experiencing rapid growth. The biopharma market size was estimated to be over $400 billion in 2024, with a projected compound annual growth rate (CAGR) of 7.56% between 2024 and 2029. The biotech sector is also growing, with a market size of nearly $500 billion in 2020 and a CAGR of 9.4% between 2021 and 2027[3].
Regulatory and Technological Impacts
The regulatory landscape is evolving to keep pace with innovation in the biopharma and biotech industries. This includes changes in clinical trial designs, the adoption of precision medicine, and the integration of AI/ML technologies. These advancements are expected to shape the future of drug development and could influence pricing and market dynamics[3].
Future Price Projections
Given the current trends and market context, here are some key points to consider for future price projections:
Industry Growth
The biopharma and biotech sectors are expected to continue growing, driven by technological innovations and evolving regulatory frameworks. This growth could lead to increased demand and potentially higher prices for drugs like IMATINIB MESYLATE[3].
Pricing Trends
Historical data shows that pharmaceutical prices in the U.S. have been increasing. For example, the median price increase for brand name drugs was 13.4% in 2022. This trend may continue, influencing the prices of specific drugs[2][4].
Regulatory Changes
Any changes to the National Drug Code system, such as the potential shift to a new format due to the depletion of 5-digit manufacturer codes, could have significant impacts on the pharmaceutical industry. However, these changes are likely to be gradual and may not immediately affect pricing[1].
Key Takeaways
- Current Pricing: The price per unit for IMATINIB MESYLATE 100 MG TAB (NDC 00378-2245) has shown slight increases in recent months.
- Market Context: Pharmaceutical prices in the U.S. are significantly higher than in other regions.
- Industry Growth: The biopharma and biotech sectors are experiencing rapid growth, which could lead to increased demand and higher prices.
- Regulatory and Technological Impacts: Evolving regulatory frameworks and technological innovations are shaping the future of drug development and pricing.
FAQs
1. What is the current price trend for IMATINIB MESYLATE 100 MG TAB (NDC 00378-2245)?
The current price trend shows slight increases over the recent months, with the price per unit ranging from $0.50016 to $0.66780[2].
2. How does the U.S. pharmaceutical pricing compare to other regions?
The average price per unit in the U.S. is significantly higher, being 5.5 times as high as in the OECD (excluding the U.S.) and 7.7 times as high as in the rest of the world (excluding the U.S.)[4].
3. What are the projected growth rates for the biopharma and biotech industries?
The biopharma market is projected to grow at a CAGR of 7.56% between 2024 and 2029, while the biotech sector is expected to grow at a CAGR of 9.4% between 2021 and 2027[3].
4. How might regulatory changes affect the pharmaceutical industry?
Regulatory changes, such as the potential reform of the National Drug Code system, could have significant impacts on the industry, including hospitals, retail pharmacies, and drug manufacturers, but these changes are likely to be gradual[1].
5. What role do technological innovations play in the biopharma and biotech industries?
Technological innovations, including precision medicine and AI/ML technologies, are expected to shape the future of drug development, making clinical trials more efficient and personalized, which could influence pricing and market dynamics[3].
Sources
-
The Future of the National Drug Code | FDB (First Databank)
-
Latest drug prices and trends for NDC 00378-2245 - DrugPatentWatch
-
5 Predictions for the Biopharma and Biotech Industries in 2025
-
ISSUE BRIEF - ASPE
-
National Drug Code Directory - FDA
